Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORS.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Biological Advances and Current Challenges for Pediatric Rhabdomyosarcoma.

Cancers·2026
Same author

Efficacy of larotrectinib in pediatric cancers with <i>NTRK</i> gene fusions.

Translational pediatrics·2026
Same author

Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3-FOXO1 rhabdomyosarcoma.

Cell death discovery·2025
Same author

MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD.

iScience·2025
Same author

IGSF10 is a RET antagonist regulating Ewing sarcoma growth and GnRH neuron migration.

Cell reports·2025

関連する実験動画

Updated: Sep 10, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.3K

ラブドミオサルコマ:顕微鏡下での分子療法の開発

Peter J Houghton1, Mary-Ann Bjornsti2

  • 1Department of Molecular Medicine, Greehey Children's Cancer Research Institute, UT Health San Antonio, San Anonio, TX, USA.

Expert opinion on therapeutic targets
|August 21, 2025
PubMed
まとめ

ラブドミオサルコマ (RMS) は,まれな小児がんである. 進歩は分子標的を明らかにしますが,新しい標的治療法と高度なRMSの改善された結果のために標準化されたテストが必要です.

キーワード:
抗体-薬物結合体 (ADCs)フュージョンネガティブ (F-N) RMS核融合陽性 (F-P) RMSラブドミオサルコマチメリック抗原受容体 (CAR) T細胞療法ミトゲン活性化タンパク質キナーゼ (MAPK) 阻害剤分子型マルチキナーゼ阻害剤

さらに関連する動画

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.5K
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.3K

関連する実験動画

Last Updated: Sep 10, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.3K
Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.5K
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.3K

科学分野:

  • 小児腫瘍学
  • 分子病理学
  • ガン治療薬

背景:

  • ラブドミオサルコマ (RMS) は,骨格筋の特徴を持つ珍しい小児固体腫瘍ですが,その細胞起源については議論されています.
  • 現在の標準的な治療法 (化学療法,放射線治療,手術) は,数十年にわたって進行したRMSの改善が限られていることが示されています.

研究 の 目的:

  • ラブドミオサルコマの 最近の分子学的進歩を振り返るため
  • 新しい治療法の標準化された臨床前試験と 分子主導の臨床試験の必要性を強調する.

主な方法:

  • ラブドミオサルコマの分子サブタイプとドライバー変異に関する最近の研究のレビュー.
  • 臨床前モデルと新興治療戦略の分析,キナーゼ阻害剤,ADC,CAR T細胞,免疫チェックポイント阻害剤を含む.

主要な成果:

  • RMSのサブタイプに異なった分子誘導因子の特定は,標的治療の可能性を示唆する.
  • 多くの分子標的薬は臨床前活性を示しているが,有効性の評価には標準化が欠けている.

結論:

  • RMSは,分子的にターゲットを合わせた治療を必要とする疾患のグループです.
  • 新規の臨床前試験アプローチと標準化された有効性評価の開発は,分子主導の臨床試験の進展と患者の成果の改善に不可欠です.